Advanced Enzymes: India drives Q2 growth as Americas slows
Key highlights
- India generated 52% of Q2 FY27 sales, with revenue rising 25% year on year to Rs 111 crore.
- Americas revenue increased 4% to Rs 57.9 crore in Q2 FY27, contributing 27% of quarterly sales.
- Europe revenue declined 10% to Rs 10.4 crore in Q2 FY27, despite H1 FY27 growth of 14%.
- Consolidated income from operations rose 16% to Rs 214.5 crore, while net profit increased 14% to Rs 51.2 crore.
powered by IRIS

Advanced Enzymes reported that India accounted for 52% of Q2 FY27 sales after revenue rose 25% year on year to Rs 111 crore. The Americas, the second-largest geography, increased 4% to Rs 57.9 crore, while Europe revenue declined 10% to Rs 10.4 crore and consolidated income from operations rose 16%.
Know Advanced Enzyme Technologies inside out
Results, valuation, peers and who's buying, in one view.
How important was India to Advanced Enzymes in Q2 FY27?
India was Advanced Enzymes' largest market in Q2 FY27, contributing 52% of geographic sales and generating Rs 111 crore, compared with Rs 88.7 crore in Q2 FY26. The Rs 22.3 crore increase represented 25% year-on-year growth and was the largest rupee increase among the five reported regions. Consolidated income from operations rose 16% year on year to Rs 214.5 crore in the quarter.
India's quarterly share was higher than its 50% contribution to Advanced Enzymes' FY26 revenue split. By contrast, the Americas represented 30% of FY26 revenue but 27% in Q2 FY27. The presentation treats India as a separate geography and defines Asia as excluding India.
India also remained the largest contributor in the first half, accounting for 50% of H1 FY27 geographic sales. Revenue for the six months reached Rs 204.7 crore, up 10% from Rs 188.6 crore in H1 FY26. The H1 increase of Rs 16.1 crore was lower than the Q2 increase of Rs 22.3 crore because the periods differ, but India represented at least half of sales in both measures.
How did Advanced Enzymes perform in the Americas?
The Americas generated Rs 57.9 crore in Q2 FY27, a 4% increase from Rs 55.4 crore a year earlier, and represented 27% of Advanced Enzymes' quarterly sales. It was the second-largest region by revenue, but its growth rate was below the 16% rise in consolidated income from operations and below India's 25% expansion.
The Americas' 27% quarterly share was below its 28% contribution in H1 FY27 and its 30% share in FY26. In the first half, Americas revenue rose 2% to Rs 114.4 crore from Rs 111.9 crore in H1 FY26. The region added Rs 2.5 crore in Q2 and also added Rs 2.5 crore across the six-month period reported in the presentation.
Advanced Enzymes' income from operations increased by Rs 30 crore year on year in Q2 FY27, from Rs 184.5 crore to Rs 214.5 crore. The Americas' Rs 2.5 crore increase was therefore smaller in absolute terms than India's Rs 22.3 crore rise. The presentation provides no customer, product, pricing or volume explanation for the regional movements.
Got a follow-up? Ask IRIS
Which overseas regions grew or declined for Advanced Enzymes?
Europe was the only reported geography where Advanced Enzymes recorded a Q2 FY27 revenue decline, with sales falling 10% to Rs 10.4 crore from Rs 11.6 crore in Q2 FY26. Europe accounted for 5% of quarterly sales, compared with 6% of H1 FY27 sales. Despite the quarterly decline, H1 Europe revenue increased 14% to Rs 23.6 crore from Rs 20.8 crore.
Asia excluding India recorded Q2 FY27 sales of Rs 27.1 crore, up 6% from Rs 25.6 crore in Q2 FY26, and accounted for 13% of sales. Its H1 FY27 revenue grew faster, increasing 19% to Rs 51.3 crore from Rs 43.3 crore. The region's quarterly share of 13% matched its first-half share and was one percentage point above its 12% geographical share in FY26.
Rest of the World posted the fastest percentage growth from a smaller base. Q2 FY27 sales rose 156% to Rs 8.1 crore from Rs 3.2 crore, lifting its quarterly share to 4% from 3% in FY26. For H1 FY27, revenue increased 54% to Rs 12.2 crore from Rs 7.9 crore, representing 3% of geographic sales.
What does Advanced Enzymes' Q2 geographic mix show?
Advanced Enzymes' Q2 FY27 geographic data show that India supplied most of the reported increase, while the Americas remained the largest overseas market but expanded more slowly. India and the Americas together accounted for 79% of quarterly sales, or Rs 168.9 crore out of Rs 214.5 crore in income from operations. India alone generated Rs 111 crore, exceeding the Rs 103.5 crore reported from all overseas regions combined.
The regional pattern was separate from the company's reported operating-segment results. Industrial Bio-Processing grew 43% year on year to Rs 36.5 crore in Q2 FY27 and represented 17% of sales, while Animal Nutrition increased 37% to Rs 26.5 crore and represented 12%. Specialized Manufacturing sales rose 25% to Rs 23.1 crore and accounted for 11%; the presentation does not connect individual segments to particular geographies.
At the consolidated level, profit from operations before other income, finance costs and exceptional items rose 22% to Rs 61.2 crore from Rs 50 crore. Group consolidated net profit increased 14% to Rs 51.2 crore from Rs 44.7 crore, while earnings per share rose 12% to Rs 4.33 from Rs 3.87. These results accompanied the 52% India share but do not establish that geographic mix as the cause of profit growth.
Conclusion
Advanced Enzymes' Q2 FY27 revenue growth was more India-led than its FY26 geographic mix. India added Rs 22.3 crore year on year and reached 52% of quarterly sales, whereas the Americas added Rs 2.5 crore and contributed 27%. Europe declined in the quarter, while Asia excluding India and Rest of the World increased from smaller revenue bases.
The presentation does not disclose a geographic target, regional plan or scheduled event. The unresolved point for subsequent reported periods is whether Americas growth improves from its 2% H1 FY27 pace and whether Europe can retain its 14% H1 increase after the 10% Q2 decline, while India maintained a 50% H1 sales share.


